Carisma Therapeutics Past Earnings Performance
Past criteria checks 0/6
Carisma Therapeutics's earnings have been declining at an average annual rate of -36.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 84.3% per year.
Key information
-36.1%
Earnings growth rate
50.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 84.3% |
| Return on equity | -327.4% |
| Net Margin | -582.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Revenue & Expenses BreakdownBeta
How Carisma Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15 | -87 | 30 | 0 |
| 30 Sep 23 | 14 | -83 | 20 | 0 |
| 30 Jun 23 | 13 | -80 | 17 | 0 |
| 31 Mar 23 | 12 | -75 | 17 | 0 |
| 31 Dec 22 | 10 | -61 | 9 | 0 |
| 30 Sep 22 | 6 | -57 | 11 | 0 |
| 30 Jun 22 | 4 | -49 | 9 | 0 |
| 31 Mar 22 | 1 | -43 | 8 | 0 |
| 31 Dec 21 | 0 | -41 | 6 | 0 |
Quality Earnings: CARM is currently unprofitable.
Growing Profit Margin: CARM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CARM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CARM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CARM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CARM has a negative Return on Equity (-327.45%), as it is currently unprofitable.